secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210605
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Q1 net loss $15.8M; cash $261.9M after $230M equity raise; NDA on track H2 2026
--------------------------------------------------------------------------------

- Net loss $15.8M ($1.20/share) vs $8.2M ($0.74) in Q1 2025; R&D spend $9.3M up from $4.1M.
- Cash, cash equivalents & short-term investments $261.9M as of Mar 31, following $230M oversubscribed equity offering in Feb 2026.
- FDA pre-NDA meeting granted for QTORIN rapamycin in microcystic LMs; NDA submission on track for H2 2026.
- Phase 3 SELVA study positive topline results; Phase 2 LOTU initiated; Phase 3 for cutaneous VMs and Phase 2 for DSAP planned H2 2026.
- Appointed Jennifer McDonough (SVP Market Access) and Kent Taylor (SVP Sales) to strengthen pre-launch commercialization team.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/0001193125-26-210605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer